Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03978767
Other study ID # 201901202
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date June 10, 2019
Est. completion date June 1, 2025

Study information

Verified date April 2024
Source Washington University School of Medicine
Contact Jonathan S Hirshberg, MD
Phone 314-362-5000
Email jhirshberg@wustl.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized non-inferiority trial of women with preeclampsia with severe features to determine if the addition of nonsteroidal anti-inflammatory drugs is inferior or non-inferior to standard analgesic bundles in their impact on postpartum hypertension.


Description:

Recently published clinical guidelines for the care of women with hypertensive disorders recommended that nonsteroidal anti-inflammatory drugs (NSAIDs) should be withheld from patients with hypertension that persists for more than one day postpartum (1). This recommendation is based in data from the general medicine literature, which suggests a role of NSAIDs in precipitating hypertension in non-pregnant adults (2,3). It may also draw from previously published case reports of post-partum hypertension that were thought to be NSAID induced (4). There has been a paucity of data from the obstetric literature to support or rebuff this recommendation. As the opioid crisis worsens in the United States, additional attention and resources have focused on limiting the use of narcotic medications. The effective employment of non-opioid analgesics has been shown to reduce narcotic use (5). Ibuprofen and other NSAIDs are the most effective and most commonly prescribed analgesics for postpartum pain, but clinicians now find themselves stuck between these recommendations and their efforts to limit unnecessary opioid prescriptions. The investigators propose a randomized controlled non-inferiority trial of women with preeclampsia comparing a postpartum analgesic protocol that includes NSAIDs, to one that excludes them. The central hypothesis is that NSAID use does not worsen hypertensive diseases of pregnancy.


Recruitment information / eligibility

Status Recruiting
Enrollment 286
Est. completion date June 1, 2025
Est. primary completion date January 31, 2025
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria: - Women at > 23 weeks gestational age undergoing vaginal or cesarean delivery at Barnes-Jewish Hospital with: - An antepartum diagnosis of preeclampsia with severe features - Pre-eclampsia with severe features will be defined as: - Elevated blood pressure = 160/110, or - Pre-eclampsia in the setting of thrombocytopenia (platelet count < 100,000), or - Impaired liver function (AST elevated to twice upper limit of normal), or - Persistent epigastric pain, or - Renal insufficiency (serum creatinine of 1.1 mg/dl or doubling of prior value), or - Pulmonary edema, or - New onset visual disturbance or headache unresponsive to therapy. Exclusion Criteria: - NSAID allergy - Allergy to acetaminophen - Antihypertensive use in this pregnancy prior to 20 weeks gestation - Chronic kidney disease or Acute kidney injury with Creatine clearance less than 60 mL/min - Inability to obtain consent - Opioid abuse disorder - Peptic ulcer disease.

Study Design


Intervention

Drug:
Ibuprofen 600 mg
NSAID pain medication to be used in the experimental bundle for postpartum analgesia
Ketorolac
NSAID analgesic to be used in the experimental bundle for postpartum analgesia in patients who underwent cesarean section
Acetaminophen
Analgesic medication to be used in both treatment arms
Oxycodone
Analgesic medication to be used in both treatment arms

Locations

Country Name City State
United States Barnes Jewish Hospital Saint Louis Missouri

Sponsors (1)

Lead Sponsor Collaborator
Washington University School of Medicine

Country where clinical trial is conducted

United States, 

References & Publications (5)

Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013 Nov;122(5):1122-1131. doi: 10.1097/01.AOG.0000437382.03963.88. No abstract available. — View Citation

Lo JO, Mission JF, Caughey AB. Hypertensive disease of pregnancy and maternal mortality. Curr Opin Obstet Gynecol. 2013 Apr;25(2):124-32. doi: 10.1097/GCO.0b013e32835e0ef5. — View Citation

Mogos MF, Salemi JL, Spooner KK, McFarlin BL, Salihu HH. Hypertensive disorders of pregnancy and postpartum readmission in the United States: national surveillance of the revolving door. J Hypertens. 2018 Mar;36(3):608-618. doi: 10.1097/HJH.0000000000001594. — View Citation

Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005 Feb 26-Mar 4;365(9461):785-99. doi: 10.1016/S0140-6736(05)17987-2. — View Citation

Viteri OA, England JA, Alrais MA, Lash KA, Villegas MI, Ashimi Balogun OA, Chauhan SP, Sibai BM. Association of Nonsteroidal Antiinflammatory Drugs and Postpartum Hypertension in Women With Preeclampsia With Severe Features. Obstet Gynecol. 2017 Oct;130(4):830-835. doi: 10.1097/AOG.0000000000002247. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary postpartum antihypertensive requirements measurement of anti-hypertensive requirements at time of discharge at the end of hospitalization, up to 7 days after randomization
Secondary Postpartum pain scores Evaluate the effect of NSAIDs on patient perception of pain From randomization to 6 weeks after randomization
Secondary Postpartum opioid use Compare the opioid requirements in each arm From randomization to 6 weeks after randomization
Secondary Mean arterial blood pressure Compare peak, average and median MAPs postpartum From randomization to 6 weeks after randomization
Secondary End organ damage Evaluate for evidence of renal, hepatic or neurological injury in the poatpartum period during hospitalization, an average of 4 days
Secondary Hospital readmission Evaluate the incidence of hospital readmission rate postpartum From randomization to 6 weeks after randomization
Secondary Continued anti-hypertensive requirement evaluate the need for antihypertensive medications at 6 weeks postpartum up to 6 weeks
See also
  Status Clinical Trial Phase
Terminated NCT04243278 - Postpartum Low-Dose Aspirin After Preeclampsia for Optimization of Cardiovascular Risk (PAPVASC) Early Phase 1
Not yet recruiting NCT03318211 - Discontinuation of Magnesium Sulfate After Delivery in Women With Severe Preeclampsia. A Randomized Controlled Trial Phase 4
Completed NCT05594056 - Transorbital Ultrasound of Optic Nerve Sheath Diameter Between Healthy Pregnant Women and Those With Severe Preeclampsia. N/A
Recruiting NCT03761888 - Nicardipine and Labetalol Effects on Cerebral Hemodynamics in Preeclampsia
Not yet recruiting NCT06373367 - Preeclampsia Educational Program Study (PrEPS) N/A
Not yet recruiting NCT04855513 - Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial N/A
Not yet recruiting NCT05232994 - Metformin and Esomeprazole For Preterm Pre-eclampsia Phase 1
Completed NCT04392375 - Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor Phase 4
Completed NCT04236258 - Comparing Nifedipine and Enalapril in Medical Resources Used in the Postpartum Period Phase 4
Completed NCT04756661 - Uterotonics for Severe Preeclampsia N/A
Active, not recruiting NCT04660032 - Nudge to Drive Transitions of Care N/A
Completed NCT04103489 - The Use of Eculizumab in HELLP Syndrome Phase 1
Enrolling by invitation NCT04794855 - Risk Prediction Model of Preeclampsia
Recruiting NCT04311749 - Expanded NIPT for Pregnancy Complications
Active, not recruiting NCT06359015 - Metformin and Esomeprazole in Preterm Pre-eclampsia Phase 4
Recruiting NCT05610774 - Optic Nerve Sheath Diameter in Pre-Eclamptic Parturient Receiving Magnesium Sulfate Combined With Dexmedetomidine N/A
Completed NCT03815110 - Preeclampsia Risk Assessment: Evaluation of Cut-offs to Improve Stratification
Completed NCT03210350 - Effect of Magnesium Sulphate on the Intracranial Pressure of Preeclamptic Patients
Completed NCT03451266 - Effects of Vitamin C Administration on Extravascular Lung Water in Patients With Severe Features of Preeclampsia Phase 1
Active, not recruiting NCT06360601 - Intravenous Labetalol Versus Hydralazine in Preeclampsia Phase 1/Phase 2